
Loading, please wait...

Loading, please wait...

The MANAS 1 AI model represents a significant leap in Indian neuroscience and medical technology. Developed by Intellihealth and led by Dr. Puneet Agarwal, this foundational platform interprets complex electrical signals from the brain. By analyzing 60,000 hours of EEG recordings, the system aims to identify neurological conditions before they become visible on traditional scans. This breakthrough could transform how clinicians approach early diagnosis for millions of patients.
Traditional diagnostic tools like MRI often fail to capture the real-time electrical nuances of brain function. Consequently, doctors must rely on visible structural changes which appear late in disease progression. The MANAS 1 AI model addresses this gap by training on data from over 25,000 patients. It features 400 million parameters designed to understand the \"basic language\" of the brain. Because it is an open-source tool, researchers can now build specialized applications for epilepsy and dementia upon this core architecture.
India currently faces a significant shortage of neurologists and psychiatrists, especially in rural areas. Therefore, late detection of brain disorders remains a major public health challenge. Since the model provides a scalable screening tool, it could empower doctors at community health centers to perform preliminary assessments. Early intervention usually reduces long-term disability and healthcare costs for families. Furthermore, the upcoming release of MANAS 2 suggests that this technology will continue to evolve rapidly.
Q1: What makes MANAS 1 different from conventional medical AI?
Unlike standard systems that analyze text or images, MANAS 1 is specifically trained to interpret EEG signals, which are the raw electrical activities of the brain. It acts as a foundational platform rather than a single-purpose tool.
Q2: Can this model be used in clinical practice immediately?
While the model is available for research on Hugging Face, any specific diagnostic tool derived from MANAS 1 requires regulatory approvals before clinicians can use it for patient care.
Q3: Which disorders can MANAS 1 help detect?
The platform is designed to support the development of tools for detecting epilepsy, dementia, and various other psychiatric and neurological conditions by decoding brainwave patterns.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


India launches MANAS 1, an open-source AI trained on 60,000 hours of EEG data to enable early detection of neurological and psychiatric disorders....
7 months ago

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today